Seribantumab - Elevation Oncology
Alternative Names: MM-121; SAR-256212Latest Information Update: 04 Oct 2024
At a glance
- Originator Merrimack Pharmaceuticals
- Developer Elevation Oncology; Merrimack Pharmaceuticals; Sanofi
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Solid tumours
Highest Development Phases
- Suspended Solid tumours
- Discontinued Gynaecological cancer; HER2 negative breast cancer; Non-small cell lung cancer; Ovarian cancer
Most Recent Events
- 19 Sep 2024 Elevation Oncology terminated the phase II CRESTONE trial for Solid tumours (Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA, Australia, Canada and South Korea (IV), due to business decision (NCT04383210)
- 11 Apr 2024 Interim pharmacodynamics data from a preclinical studies in HER2 expressing cancer released by Elevation Oncology
- 14 Apr 2023 Safety and efficacy data from a phase II CRESTONE trial in Solid tumours presented at the 114th Annual Meeting of the American Association for Cancer Research (AACR-2023)